The roles of mediator complex in cardiovascular diseases

Concetta Schiano, Amelia Casamassimi, Maria Teresa Vietri, Monica Rienzo, Claudio Napoli

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Despite recent treatment advances, an increase in cardiovascular diseases (CVD) mortality is expected for the next years. Mediator (MED) complex plays key roles in eukaryotic gene transcription. Currently, while numerous studies have correlated MED alterations with several diseases, like cancer or neurological disorders, fewer studies have investigated MED role in CVD initiation and progression. The first finding of MED involvement in these pathologies was the correlation of missense mutations in MED13L gene with transposition of the great arteries. Nowadays, also MED13 and MED15 have been associated with human congenital heart diseases and others could be added, like MED12 that is involved in early mouse development and heart formation. Interestingly, a missense mutation in MED30 gene causes a progressive cardiomyopathy in homozygous mice suggesting a potential role for this subunit also in human CVDs. Moreover, several subunits like MED1, MED13, MED14, MED15, MED23, MED25 and CDK8 exert important roles in glucose and lipid metabolism. Although these evidences derive from in vitro and animal model studies, they indicate that their deregulation may have a significant role in human CVD-related metabolic disorders. Finally, alternative transcripts of MED12, MED19 and MED30 are differently expressed in circulating endothelial progenitor cells thus suggesting they can play a role in the field of regenerative medicine. Overall, further functional studies exploring MED role in human CVD are warranted. The results could allow identifying novel biomarkers to use in combination with imaging techniques for early diagnosis; otherwise, they could be useful to develop targets for novel therapeutic approaches.

Original languageEnglish
Pages (from-to)444-451
Number of pages8
JournalBiochimica et Biophysica Acta - Gene Regulatory Mechanisms
Volume1839
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Mediator Complex
Cardiovascular Diseases
Missense Mutation
Genes
Transposition of Great Vessels
Regenerative Medicine
Nervous System Diseases
Cardiomyopathies
Lipid Metabolism
Disease Progression
Early Diagnosis
Heart Diseases
Deregulation
Animal Models
Biomarkers
Endothelial cells
Pathology
Transcription
Glucose
Mortality

Keywords

  • Cardiovascular diseases
  • Congenital heart diseases
  • Endothelial progenitor cells
  • Energy homeostasis
  • Mediator complex
  • Pluripotency

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Genetics
  • Molecular Biology
  • Structural Biology

Cite this

The roles of mediator complex in cardiovascular diseases. / Schiano, Concetta; Casamassimi, Amelia; Vietri, Maria Teresa; Rienzo, Monica; Napoli, Claudio.

In: Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, Vol. 1839, No. 6, 2014, p. 444-451.

Research output: Contribution to journalArticle

Schiano, Concetta ; Casamassimi, Amelia ; Vietri, Maria Teresa ; Rienzo, Monica ; Napoli, Claudio. / The roles of mediator complex in cardiovascular diseases. In: Biochimica et Biophysica Acta - Gene Regulatory Mechanisms. 2014 ; Vol. 1839, No. 6. pp. 444-451.
@article{e72625541ccb4467aae97a60d19641f3,
title = "The roles of mediator complex in cardiovascular diseases",
abstract = "Despite recent treatment advances, an increase in cardiovascular diseases (CVD) mortality is expected for the next years. Mediator (MED) complex plays key roles in eukaryotic gene transcription. Currently, while numerous studies have correlated MED alterations with several diseases, like cancer or neurological disorders, fewer studies have investigated MED role in CVD initiation and progression. The first finding of MED involvement in these pathologies was the correlation of missense mutations in MED13L gene with transposition of the great arteries. Nowadays, also MED13 and MED15 have been associated with human congenital heart diseases and others could be added, like MED12 that is involved in early mouse development and heart formation. Interestingly, a missense mutation in MED30 gene causes a progressive cardiomyopathy in homozygous mice suggesting a potential role for this subunit also in human CVDs. Moreover, several subunits like MED1, MED13, MED14, MED15, MED23, MED25 and CDK8 exert important roles in glucose and lipid metabolism. Although these evidences derive from in vitro and animal model studies, they indicate that their deregulation may have a significant role in human CVD-related metabolic disorders. Finally, alternative transcripts of MED12, MED19 and MED30 are differently expressed in circulating endothelial progenitor cells thus suggesting they can play a role in the field of regenerative medicine. Overall, further functional studies exploring MED role in human CVD are warranted. The results could allow identifying novel biomarkers to use in combination with imaging techniques for early diagnosis; otherwise, they could be useful to develop targets for novel therapeutic approaches.",
keywords = "Cardiovascular diseases, Congenital heart diseases, Endothelial progenitor cells, Energy homeostasis, Mediator complex, Pluripotency",
author = "Concetta Schiano and Amelia Casamassimi and Vietri, {Maria Teresa} and Monica Rienzo and Claudio Napoli",
year = "2014",
doi = "10.1016/j.bbagrm.2014.04.012",
language = "English",
volume = "1839",
pages = "444--451",
journal = "Biochimica et Biophysica Acta - Gene Regulatory Mechanisms",
issn = "1874-9399",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - The roles of mediator complex in cardiovascular diseases

AU - Schiano, Concetta

AU - Casamassimi, Amelia

AU - Vietri, Maria Teresa

AU - Rienzo, Monica

AU - Napoli, Claudio

PY - 2014

Y1 - 2014

N2 - Despite recent treatment advances, an increase in cardiovascular diseases (CVD) mortality is expected for the next years. Mediator (MED) complex plays key roles in eukaryotic gene transcription. Currently, while numerous studies have correlated MED alterations with several diseases, like cancer or neurological disorders, fewer studies have investigated MED role in CVD initiation and progression. The first finding of MED involvement in these pathologies was the correlation of missense mutations in MED13L gene with transposition of the great arteries. Nowadays, also MED13 and MED15 have been associated with human congenital heart diseases and others could be added, like MED12 that is involved in early mouse development and heart formation. Interestingly, a missense mutation in MED30 gene causes a progressive cardiomyopathy in homozygous mice suggesting a potential role for this subunit also in human CVDs. Moreover, several subunits like MED1, MED13, MED14, MED15, MED23, MED25 and CDK8 exert important roles in glucose and lipid metabolism. Although these evidences derive from in vitro and animal model studies, they indicate that their deregulation may have a significant role in human CVD-related metabolic disorders. Finally, alternative transcripts of MED12, MED19 and MED30 are differently expressed in circulating endothelial progenitor cells thus suggesting they can play a role in the field of regenerative medicine. Overall, further functional studies exploring MED role in human CVD are warranted. The results could allow identifying novel biomarkers to use in combination with imaging techniques for early diagnosis; otherwise, they could be useful to develop targets for novel therapeutic approaches.

AB - Despite recent treatment advances, an increase in cardiovascular diseases (CVD) mortality is expected for the next years. Mediator (MED) complex plays key roles in eukaryotic gene transcription. Currently, while numerous studies have correlated MED alterations with several diseases, like cancer or neurological disorders, fewer studies have investigated MED role in CVD initiation and progression. The first finding of MED involvement in these pathologies was the correlation of missense mutations in MED13L gene with transposition of the great arteries. Nowadays, also MED13 and MED15 have been associated with human congenital heart diseases and others could be added, like MED12 that is involved in early mouse development and heart formation. Interestingly, a missense mutation in MED30 gene causes a progressive cardiomyopathy in homozygous mice suggesting a potential role for this subunit also in human CVDs. Moreover, several subunits like MED1, MED13, MED14, MED15, MED23, MED25 and CDK8 exert important roles in glucose and lipid metabolism. Although these evidences derive from in vitro and animal model studies, they indicate that their deregulation may have a significant role in human CVD-related metabolic disorders. Finally, alternative transcripts of MED12, MED19 and MED30 are differently expressed in circulating endothelial progenitor cells thus suggesting they can play a role in the field of regenerative medicine. Overall, further functional studies exploring MED role in human CVD are warranted. The results could allow identifying novel biomarkers to use in combination with imaging techniques for early diagnosis; otherwise, they could be useful to develop targets for novel therapeutic approaches.

KW - Cardiovascular diseases

KW - Congenital heart diseases

KW - Endothelial progenitor cells

KW - Energy homeostasis

KW - Mediator complex

KW - Pluripotency

UR - http://www.scopus.com/inward/record.url?scp=84900497024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900497024&partnerID=8YFLogxK

U2 - 10.1016/j.bbagrm.2014.04.012

DO - 10.1016/j.bbagrm.2014.04.012

M3 - Article

VL - 1839

SP - 444

EP - 451

JO - Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

JF - Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

SN - 1874-9399

IS - 6

ER -